## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Avi Ashkenazi, et al.

Docket No.:

39780-2730P1C23

Serial No.:

09/993,748

Group Art Unit:

1647

Filing Date:

November 14, 2001

Examiner:

Robert Landsman

For:

PRO1346 POLYPEPTIDES

Express Mailing Label No.: EL 977 673 793 US

Mailing Date: September 9, 2004

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

 1110		ent qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
	(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  OR
	(2)	It is being filed within 3 months of entry of a national stage OR
	(3)	It is being filed before the mail date of the first Office Action on the merits OR
	(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

×	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:				
		a certification as specified in §1.97(e)	is provided below; or		
	$\boxtimes$	a fee of \$180.00 as set forth in \$1.17(p the payment of other papers filed toget	) is authorized below, enclosed, or included with ther with this statement.		
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:				
	A.	a certification as specified in §1.97(e)	is completed below; and		
	B.	a petition under 37 C.F.R. §1.97(d) required submitted herewith; and	questing consideration of this statement is		
	C.	a fee of \$180.00 as set forth in \$1.17(i) the payment of other papers filed toget	(1) is authorized below, enclosed, or included with ther with this statement.		
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641</u> (Docket No. <u>39780-2730P1C23</u> ).				
		F	Respectfully submitted,		
Dated:	Septer	mber 9, 2004 F	By: Raphne Reddy  Daphne Reddy, Ph.D.  Reg. No. 53,507		

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 09157/35489

275 Middlefield Road
Maria Park CA 04025 250

Menlo Park, CA 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

## **SERIAL NO.:** ATTY. DOCKET NO.: **INFORMATION DISCLOSURE** 09/993,748 **STATEMENT** 39780-2730P1C23 APPLICANT: Ashkenazi, et al. PTO-1449 **GROUP: 1647 FILING DATE: 11/14/01 U.S. PATENT DOCUMENTS CLASS** SUBCLASS FILING DATE **EXAMINER'S** PATENT NO. NAME INITIALS FOREIGN PATENT DOCUMENTS TRANSLATION COUNTRY **SUBCLASS** PATENT NO. DATE **CLASS EXAMINER'S INITIALS** YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Dayhoff, Accession No.: P AAB65250, WO200073454-A1, Pub. Date: Dec. 7, 2000, Ashkenazi, A.J. et al. Dayhoff, Accession No.: P\_AAY66727, WO9963088-A2, Pub. Date: Dec. 9, 1999, Baker, K. et. al. Dayhoff, Accession No.: P\_AAB33444, WO200053758-A2, Pub. Date: Sept. 14, 2000, Ashkenazi, A.J. et.al. GenBank, Accession No.: P\_AAC58609, WO200053758-A2, Pub. Date: Sept. 14, 2000, Ashkenazi, A.J. et.al. GenBank, Accession No.: P AAF44217, WO200073454-A1, Pub. Date: Dec. 7, 2000, Ashkenazi, A.J. et. al. GenBank, Accession No.: P AAZ65071, WO9963088-A2, Pub. Date: Dec. 9, 1999, Baker, K. et.al. DATE CONSIDERED **EXAMINER**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.